Nexcella Begins Production of CAR-T Cell Therapy Engineering Batches at US Manufacturing Site

Article

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.

Nexcella, a subsidiary of US-based Immix Biopharma and a clinical-stage biopharmaceutical company, announced on May 26, 2023 that it has begun producing engineering batches of NXC-201, its lead candidate and a chimeric antigen receptor T cell (CAR-T) therapy, at its US manufacturing site.

These engineering batches are intended to support the company’s planned expansion into the United States of an ongoing Phase Ib/IIa clinical study (NEXICART-1 [NCT04720313]) in adults with relapsed or refractory multiple myeloma and amyloid light chain (AL) amyloidosis. NXC-201 is a novel B-cell maturation antigen (BCMA)-targeted CAR-T cell therapy. The commencement of these engineering batches represents a crucial next step in transferring Nexcella’s existing CAR-T good manufacturing practice manufacturing process to the US, according to a company press release.

“We are working tirelessly to bring NXC-201 to US patients,” said Ilya Rachman, executive chairman of Nexcella, in the press release. “NXC-201 is the first CAR-T being developed in AL amyloidosis, and in multiple myeloma, patients face significant obstacles when seeking BCMA-targeted CAR-T treatments [such as] NXC-201. We look forward to continuing to advance NXC-201 as we work to improve treatment outcomes for patients in the US suffering from AL amyloidosis and multiple myeloma.”

“Today, 95% of US medical centers are unable to offer CAR-T cell therapy,” said Gabriel Morris, president of Nexcella, in the release. “NXC-201 has already been trialed in over 50 patients, demonstrating a [one to two]-day median short side-effect duration, which offers potential to become the first out-patient CAR-T, potentially reducing hospitalization costs up to 80% and enabling dosing in 95% of US medical centers today unable to offer CAR-T cell therapy.”

Source: Nexcella

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.